Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Upping the ante on antibodies

Nature Biotechnology volume 23, pages 1065–1072 (2005)Cite this article

The current generation of antibodies has done more than make a few companies rich. It has laid the groundwork for ambitious companies to move to maturity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Anatomy of an optimized antibody.
Figure 2: By fusing the minimal binding domains of two antibodies that recognize either the immune cell or the target cell, a small bispecific antibody (green and red) is created that can now physically link immune cells and pathogenic cells.
Figure 3: DataMonitor assessed antibody companies in terms of maturity, from technology providers to fully integrated drug companies.

References

  1. Evans, D. & Das, R. Monoclonal Antibodies: Evolving into a $30 Billion Market (DataMonitor, London, UK, 2005).

    Google Scholar 

  2. Mitchell, P. Next generation monoclonals less profitable than trailblazers? Nat. Biotechnol. 23, 906 (2005).

    Article  CAS  Google Scholar 

  3. Presta, L. Antibody engineering for therapeutics. Curr. Opin. Struct. Biol. 13, 519–526 (2003).

    Article  CAS  Google Scholar 

  4. Lu, D. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J. Biol. Chem. 279, 2856–2865 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Monya Baker is a freelance writer based in San Francisco, California, USA. Additional reporting was done by Phil E. Ross, a freelance writer based in Forest Hills, NY, USA.

Authors
  1. Monya Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baker, M. Upping the ante on antibodies. Nat Biotechnol 23, 1065–1072 (2005). https://doi.org/10.1038/nbt0905-1065

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0905-1065

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing